Just for a little comparison...
1999-2002 Preclinical and clinical studies
2003 Launch for rheumatoid arthritis (at 4 years from discovery) 200 million in sales (roughly)
2005 Launch for psoriatic arthritis (at 6 years from discovery)
2007 Launch for Crohn's (at 8 years from discovery)
2014 IMS health recognizes Humira as world's best selling drug (at 15 years from discovery)
2007 - 2008 discovery (APD356) and early tests
2008 - 2010 clinical trials and initial rejection
2012 - Approval
2013 - DEA scheduling and launch for obesity (6 years from discovery)
2022 - That would be the same point in Belviq's life cycle as Humira is in 2015 with 4-5 more years to go.
Now, I wonder how many Abbott investors were all pissed about having to wait 2 years for each additional indication? And how many were belly-aching in early 2004 about how 200 million in sales would mean this could never ever become a blockbuster, let alone being deemed the world's best selling drug by IMS...